Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Global Healthcare Advisors initiates transaction, serves as advisor
April 15, 2020
By: Contract Pharma
Contract Pharma Staff
Earlier this year, Global Healthcare Advisors (GHA) announced the acquisition of Canada’s Dalton Pharma Services by Japan’s Seikagaku Corporation (SKK). With the acquisition of Dalton, SKK adds high value-added one-stop contract development and manufacturing (CDMO) services, including the manufacturing of chemosynthesis products and active pharmaceutical ingredients (API), and API process development for pharmaceutical companies at a time of strong industry growth. Dalton’s services also include the manufacturing of investigational drugs in the development stage and optimization of manufacturing conditions. As part of the transaction, SKK obtains Dalton’s: • Cultivated chemosynthesis technology; • Internal knowledge related to the development of drug manufacturing processes; and • GMP-certified North American drug manufacturing base. SKK plans to leverage these additions to begin in-house manufacturing of chemosynthesis products used for research and other purposes, which SKK currently produces by outsourced contract manufacturing. SKK also plans to transfer the manufacturing of investigational drugs and selected SKK pharmaceutical products to Dalton while expanding its CDMO business and continuing its exceptional service to current clients. GHA initiated this transaction and advised SKK on its acquisition. “The acquisition of Dalton represents an exciting addition for SKK and positions us well for expansion and continued success in the fast-growing pharmaceutical services industry,” said Ken Mizutani, president and chief executive officer, SKK. “The team at GHA was instrumental at all stages of this transaction, and we appreciate their professionalism and diligence.” Larry Carter, managing partner, GHA, said, “The intricacies of this particular transaction required full-team commitment and a strategic vision on behalf of all parties, which we are proud to have brought to fruition. GHA’s efforts were essential in sourcing, negotiating, and managing all phases of the diligence process for this transaction.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !